Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients

Thomas Hartung; Sonja Von Aulock; Marcus Freitag; Stefan Höxtermann; Markus Stücker; Klaus Hoffmann; Peter Altmeyer; Andrea Kottke; Albrecht Wendel

doi:10.1006/cyto.2000.0752

Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients

Thomas Hartung, Sonja Von Aulock, Marcus Freitag, Stefan Höxtermann, Markus Stücker, Klaus Hoffmann, Peter Altmeyer, Andrea Kottke, Albrecht Wendel

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n =9) or 2 μg/kg (n = 14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by Bow doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response. (C) 2000 Academic Press.

Original language	English (US)
Pages (from-to)	1570-1574
Number of pages	5
Journal	Cytokine
Volume	12
Issue number	10
DOIs	https://doi.org/10.1006/cyto.2000.0752
State	Published - 2000
Externally published	Yes

Keywords

Blood
Cytokines
Growth factors
Human
Inflammation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Biochemistry
Hematology
Molecular Biology

Access to Document

10.1006/cyto.2000.0752

Cite this

@article{2620b539b0f5465895109c2223d924c7,

title = "Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients",

abstract = "We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n =9) or 2 μg/kg (n = 14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by Bow doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response. (C) 2000 Academic Press.",

keywords = "Blood, Cytokines, Growth factors, Human, Inflammation",

author = "Thomas Hartung and {Von Aulock}, Sonja and Marcus Freitag and Stefan H{\"o}xtermann and Markus St{\"u}cker and Klaus Hoffmann and Peter Altmeyer and Andrea Kottke and Albrecht Wendel",

year = "2000",

doi = "10.1006/cyto.2000.0752",

language = "English (US)",

volume = "12",

pages = "1570--1574",

journal = "Cytokine",

issn = "1043-4666",

publisher = "Academic Press Inc.",

number = "10",

}

TY - JOUR

T1 - Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients

AU - Hartung, Thomas

AU - Von Aulock, Sonja

AU - Freitag, Marcus

AU - Höxtermann, Stefan

AU - Stücker, Markus

AU - Hoffmann, Klaus

AU - Altmeyer, Peter

AU - Kottke, Andrea

AU - Wendel, Albrecht

PY - 2000

Y1 - 2000

N2 - We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n =9) or 2 μg/kg (n = 14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by Bow doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response. (C) 2000 Academic Press.

AB - We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n =9) or 2 μg/kg (n = 14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by Bow doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response. (C) 2000 Academic Press.

KW - Blood

KW - Cytokines

KW - Growth factors

KW - Human

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0033789721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033789721&partnerID=8YFLogxK

U2 - 10.1006/cyto.2000.0752

DO - 10.1006/cyto.2000.0752

M3 - Article

C2 - 11023676

AN - SCOPUS:0033789721

VL - 12

SP - 1570

EP - 1574

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 10

ER -

Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this